摘要
目的探讨2型糖尿病(T2DM)患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应的影响因素。方法回顾性分析186例在原降糖方案不变的基础上首次应用聚乙二醇洛塞那肽治疗T2DM患者的临床资料,依据治疗2周以内是否发生胃肠道不良反应分为发生胃肠道不良反应组(A组,40例)和未发生胃肠道不良反应组(B组,146例)。比较两组患者一般资料及应用聚乙二醇洛塞那肽治疗前生化指标的差异。采用多因素logistic回归分析T2DM患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应的独立影响因素。绘制ROC曲线评估相关指标对T2DM患者应用聚乙二醇洛塞那肽发生胃肠道不良反应的预测价值。结果A组BMI低于B组(P<0.01),而年龄、T2DM病程和既往消化道疾病史比例高于B组(P<0.05)。多因素logistic回归分析显示,年龄越大和既往消化道疾病史是T2DM患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应的独立危险因素(P<0.05),高BMI水平是T2DM患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应的独立保护因素(P<0.01)。ROC曲线分析显示,年龄、BMI和既往消化道疾病史联合预测T2DM患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应的AUC为0.887[95%CI(0.838~0.936),P<0.01],预测灵敏度与特异度分别为95.0%与79.5%。结论BMI、年龄及既往消化道疾病史与T2DM患者应用聚乙二醇洛塞那肽发生胃肠道不良反应密切相关,三者联合对T2DM患者应用聚乙二醇洛塞那肽治疗发生胃肠道不良反应有一定预测价值。
Objective To analyze the influencing factors for gastrointestinal adverse reactions in the patients with type 2diabetes mellitus(T2DM)treated with polyethylene glycol loxenatide.Methods The clinical data of 186T2DM patients treated with polyethylene glycol loxenatide for the first time on the basis of the original hypoglycemic regimen were retrospectively analyzed.According to whether gastrointestinal adverse reactions occurred within 2weeks of treatment,the patients were divided into two groups of A(with gastrointestinal adverse reactions,40cases)and B(without gastrointestinal adverse reactions,146cases).The general information and differences in biochemical indicators before treatment with polyethylene glycol loxenatide were compared between the two groups.Multivariate logistic regression analysis was used to analyze the influencing factors for the gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide.The ROC curve was plotted to evaluate the predictive value of relevant indicators for gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide.Results The BMI of group A was lower than that of group B(P<0.01),while the age,T2DM course,and the proportion of the patients with gastrointestinal diseases history were more in group A than those in group B(P<0.05).Multivariate logistic regression analysis showed that older age and history of gastrointestinal diseases were the independent risk factors for gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide(P<0.05),while higher level of BMI was an independent protective factor for gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide(P<0.01).ROC curve analysis showed that the AUC of combined use of BMI,age and history of gastrointestinal diseases in predicting the occurrence of gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide was 0.887[95%CI(0.838-0.936),P<0.01],and the predictive sensitivity and specificity were 95.0%and 79.5%,respectively.Conclusion BMI,age and history of gastrointestinal diseases are closely related to the occurrence of gastrointestinal adverse reactions in T2DM patients treated with polyethylene glycol loxenatide,in whom combined use of the three factors has a certain predictive value for the occurrence of gastrointestinal adverse reactions.
作者
杨腾
王国凤
赵仁豪
王娜
YANG Teng;WANG Guofeng;ZHAO Renhao(Graduate Training Base,Jinzhou Medical University,Lianyungang First People's Hospital,Lianyungang 222000,CHINA)
出处
《江苏医药》
CAS
2024年第4期338-342,共5页
Jiangsu Medical Journal
基金
江苏省老龄健康科研项目(LKM2022065)
连云港市卫生健康科技项目(202206)
连云港市老龄健康科研项目(L202105)
连云港高新区科技项目(ZD201931)
南京医科大学康达学院科研发展基金课题(KD2019KYJJYB014)。
关键词
聚乙二醇洛塞那肽
胃肠道不良反应
2型糖尿病
Polyethylene glycol loxenatide
Gastrointestinal adverse reactions
Type 2 diabetes mellitus
作者简介
通信作者:王国凤,E-mail:nfmwangguofeng@126.com。
